Moreover, according to the Kaplan–Meier analysis of overall survival (OS) and disease-free survival (DFS), the prognosis of GBM patients with high expression level of CD81 was markedly worse than that with low level of CD81 (Figure 1F,G). This evidence concerns the gene CD81 and glioblastoma.